Cancer News and Research

Latest Cancer News and Research

HR status defines two different subsets of HER2 positive cancers

Human epidermal growth factor (HER2) positive breast cancers are often treated with the same therapy regardless of hormone receptor status. New research published in BioMed Central's open access journal Breast Cancer Research shows that women whose HER2 positive cancer was also hormone (estrogen and progesterone) receptor (HR) negative had an increased risk of early death, and that their cancer was less likely to recur in bone than those whose cancer retained hormone sensitivity.

1 Oct 2012

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

Eli Lilly and Company today announced new data from two Phase II ramucirumab (IMC-1121B) trials in patients with non-small cell lung cancer (NSCLC).

1 Oct 2012

September issue of JNCCN publishes two prostate cancer articles

Julio M. Pow-Sang, M.D., chair of Moffitt Cancer Center's Department of Genitourinary Oncology, and colleagues have published two prostate cancer articles in the September issue of JNCCN - The Journal of the National Comprehensive Cancer Network. The articles review and clarify recent updates made to the National Comprehensive Cancer Network's (NCCN) guidelines for the screening and treatment of prostate cancer.

29 Sep 2012

Study finds differences and similarities between iPSCs and cancer cells

UC Davis investigators have found new evidence that a promising type of stem cell now being considered for a variety of disease therapies is very similar to the type of cells that give rise to cancer. The findings suggest that although the cells -- known as induced pluripotent stem cells (iPSCs) -- show substantial promise as a source of replacement cells and tissues to treat injuries, disease and chronic conditions, scientists and physicians must move cautiously with any clinical use because iPSCs could also cause malignant cancer.

29 Sep 2012

Sorafenib does not improve overall survival among patients with NSCLC

Treatment with the drug sorafenib as a third or fourth line therapy does not result in improved overall survival among patients with advanced non-small cell lung cancer (NSCLC), according to findings released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. However, a post-hoc biomarker analysis of the trial data that was also presented suggests that patients with EGFR-mutant tumors may benefit.

29 Sep 2012

ARIAD announces initial results from AP26113 Phase 1/2 trial on non-small cell lung cancer

ARIAD Pharmaceuticals, Inc. today announced the initial clinical results on its investigational, tyrosine-kinase inhibitor, AP26113, in patients with advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial.

29 Sep 2012

First report to study clonal population of maxillary sinus carcinoma

Knowing how tumors evolve can lead to new treatments that could help prevent cancer from recurring, according to a study published today by the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare.

29 Sep 2012

Nearly 20% of people develop PTSD symptoms after low back fusion surgery

Nearly 20 percent of people who underwent low back fusion surgery developed post-traumatic stress disorder symptoms associated with that surgery, according to a recent Oregon Health & Science University study published in the journal Spine.

29 Sep 2012

Atrazine may increase risk of choanal atresia

A common herbicide used in the United States may be linked to an increased risk of a congenital abnormality of the nasal cavity known as choanal atresia, say researchers at Baylor College of Medicine and other Texas institutions.

29 Sep 2012

Drug combinations show promise against metastatic melanoma

Promising new data on drug combinations to treat metastatic melanoma are presented at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

29 Sep 2012

New studies reveal real economic and human costs of caring for cancer patients in Europe

New studies that reveal for the first time the real economic and human costs of caring for cancer patients in Europe will be presented during the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

29 Sep 2012

Synta announces results from ganetespib Phase 2b trial on NSCLC

Synta Pharmaceuticals Corp. today announced results from an interim analysis of the Phase 2b portion of the GALAXY trial, a global, randomized, multi-center Phase 2b/3 study designed to evaluate the efficacy and safety of the Company's lead Hsp90 inhibitor, ganetespib, as second-line treatment for advanced non-small cell lung cancer (NSCLC).

29 Sep 2012

Exelixis announces preliminary results from BRIM7 Phase Ib trial on BRAFV600 mutated MM

Exelixis, Inc. today announced preliminary results from BRIM7, an ongoing Phase Ib trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor GDC-0973 in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.

29 Sep 2012

Study to look at whether maternal exercise during pregnancy can reduce risk of cancer in offspring

If a mother exercises during her pregnancy, will that benefit her children? Researchers at the University of Kentucky have initiated studies to look into the idea: a group from the UK Graduate Center for Nutritional Sciences has received a $100,000 grant from the National Institutes of Health to study whether maternal exercise during pregnancy can lead to a reduced risk of cancer in offspring.

29 Sep 2012

New trial data shows improvements in treatment of esophageal and gastrointestinal cancers

New trial data showing improvements in the treatment of esophageal and gastrointestinal cancers were released today at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

29 Sep 2012

JAAD to publish Sensus Healthcare’s superficial radiotherapy study on non melanoma skin cancer

Sensus Healthcare is pleased to announce the acceptance and publication of the most comprehensive study to date on treating Non Melanoma Skin Cancer (NMSC) with superficial radiotherapy (SRT) in the Journal of the American Academy of Dermatology (JAAD).

29 Sep 2012

PLOS ONE journal releases report on validation of Falcon Genomics' Cancer BioChip System

The online journal PLOS ONE released a scientific report on the validation of Falcon Genomics' Cancer BioChip System (CBCS) as a tool for identifying inhibitors of breast cancer.

29 Sep 2012

State highlights: Free Calif. health care clinic a big draw; New Calif. law could mean mammogram alternatives

Many of the 4,800 people seeking care at the annual massive free clinic this weekend will become eligible for health insurance in 2014 when the national law takes effect. Organizers said raising awareness about the health care changes is crucial.

29 Sep 2012

Hackensack University Medical Center announces joint venture with community physicians and USPI

Hackensack University Medical Center has announced a joint venture partnership with community physicians and United Surgical Partners International (USPI) in the acquisition and operation of two ambulatory surgery centers (ASCs) in Bergen County: Hackensack Endoscopy Center (HEC) and Endoscopy Center of Bergen County (ECBC).

29 Sep 2012

Mount Sinai surgeon offers tips to prevent prostate cancer

World-renowned Mount Sinai robotic prostate surgeon, Dr. David Samadi, devotes much of his time to prostate cancer education domestically and internationally. "My SMART robotic prostate removal surgery saves lives, but what men really want to know is how to prevent prostate cancer in the first place," shares Dr. Samadi.

29 Sep 2012

Cancer News and Research

Latest Cancer News and Research

HR status defines two different subsets of HER2 positive cancers

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

September issue of JNCCN publishes two prostate cancer articles

Study finds differences and similarities between iPSCs and cancer cells

Sorafenib does not improve overall survival among patients with NSCLC

ARIAD announces initial results from AP26113 Phase 1/2 trial on non-small cell lung cancer

First report to study clonal population of maxillary sinus carcinoma

Nearly 20% of people develop PTSD symptoms after low back fusion surgery

Atrazine may increase risk of choanal atresia

Drug combinations show promise against metastatic melanoma

New studies reveal real economic and human costs of caring for cancer patients in Europe

Synta announces results from ganetespib Phase 2b trial on NSCLC

Exelixis announces preliminary results from BRIM7 Phase Ib trial on BRAFV600 mutated MM

Study to look at whether maternal exercise during pregnancy can reduce risk of cancer in offspring

New trial data shows improvements in treatment of esophageal and gastrointestinal cancers

JAAD to publish Sensus Healthcare’s superficial radiotherapy study on non melanoma skin cancer

PLOS ONE journal releases report on validation of Falcon Genomics' Cancer BioChip System

State highlights: Free Calif. health care clinic a big draw; New Calif. law could mean mammogram alternatives

Hackensack University Medical Center announces joint venture with community physicians and USPI

Mount Sinai surgeon offers tips to prevent prostate cancer

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Newsletters you may be interested in